Showing 4128 results for "als"

Vocal Cord Spasms in ALS May Be Triggered by Excessive Saliva

Although not thought common, laryngospasm — the sudden contraction of the vocal cords that makes speaking and breathing temporarily difficult — does affect some with amyotrophic lateral sclerosis (ALS), a study reported. Excess saliva irritating the vocal cords was the most notable trigger for laryngospasm in their work, the researchers…

Antisense Therapy Safely Dampens Mutant C9orf72 in ALS Patient

An experimental antisense oligonucleotide that works to suppress the mutant C9orf72 gene — a cause of amyotrophic lateral sclerosis (ALS) — safely lowered the production of damaging proteins and other molecules in a patient in a pilot trial. “While other teams have documented that this gene can be suppressed in cells…

Musings About the Language of ALS

During my professional years working in a hospital environment, we had to be familiar with using medical jargon. Some words sounded odd to my nonmedical ears, while others had double meanings. A few favorites I still remember are “idiopathic,” which refers to something with an unknown cause, and “unremarkable,” which…

Gut Microbiome Changes Evident Before ALS Onset, Study Finds

A mouse model of amyotrophic lateral sclerosis (ALS) carrying a mutation in the SOD1 gene showed alterations in the gut microbiome, followed by motor impairments and defects in enteric nervous system — the gut’s own autonomous nervous system — compared with healthy mice, a study found. These microbiome changes occurred…

Eikonoklastes Acquires License to Potential ALS Gene Therapy

Eikonoklastes Therapeutics has added a candidate gene therapy for amyotrophic lateral sclerosis (ALS) and other neurodegenerative diseases to its pipeline. The announcement follows the completion of a licensing agreement with the University of California San Diego. Brian Head, PhD, a professor with the university’s department of anesthesiology, and…

With Likely Diagnosis, Target ALS Founder Refocuses

Note: This story was updated Jan. 25, 2022, to clarify that Target ALS has raised $90 million since its inception in 2010. Amyotrophic lateral sclerosis (ALS) has been a part of Daniel Doctoroff’s life for more than two decades. His father, Martin Doctoroff, died of the disease in 2002, and…